Showing results (1-10 of 61) with videos related to
Sort By:
Pageof 7
Frontiers in Oncology|November 28, 2022
Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatmentMeng Yuan, Yirui Zhai, Zhouguang HuiRadiation Oncology (London, England)|January 25, 2023
Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in ChinaShujie Zhou, Yirui Zhai, Kaikai Zhao, et al.Translational Lung Cancer Research|January 13, 2023
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016-2030Yirui Zhai, Zhouguang Hui, Wanqing Chen, et al.The Thoracic and Cardiovascular Surgeon|May 30, 2019
Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic CarcinomaYirui Zhai, Zhouguang Hui, Yushun Gao, et al.Thoracic Cancer|July 30, 2020
Combined neat model for the prognosis of postoperative stage III-N2 non-small cell lung cancerYirui Zhai, Zhouguang Hui, Yu Men, et al.Frontiers in Oncology|December 17, 2020
Myasthenia Gravis Is Not an Independent Prognostic Factor of Thymoma: Results of a Propensity Score Matching Trial of 470 PatientsYirui Zhai, Yong Wei, Zhouguang Hui, et al.Tumori|November 11, 2020
Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasmsYirui Zhai, Dazhi Chen, Yushun Gao, et al.Cancer Biology & Therapy|January 21, 2012
Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapyHongxia Zhu, Zaozao Wang, Qing Xu, et al.Oncotarget|April 22, 2017
The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)Yu Men, Yang Luo, Yirui Zhai, et al.Cancer Cell International|March 30, 2022
MiR-323a-3p acts as a tumor suppressor by suppressing FMR1 and predicts better esophageal squamous cell carcinoma outcomeYu Men, Yirui Zhai, Lihong Wu, et al.Pageof 7